Clinical trials: Giant Lymph Node Hyperplasia
Idiopathic Multicentric Castleman's Disease
BCD Regimen in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD)
To explore the effectiveness and safety of bortezomib, cyclophosphamide and dexamethasone (BCD regimen) in newly diagnosed idiopathic Multicentric Castleman's disease (iMCD) patients.
- Trial name
- NCT03982771
- Testing
- Bortezomib, Cyclophosphamide, Dexamethason
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
Lymphoma, Primary Effusion
Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease
Background: Primary effusion lymphoma (PEL), plasmablastic lymphoma (PBL), and Multicentric Castleman Disease (MCD) are aggressive forms of cancer that affects cells in the immune system and lymph nodes.
- Trial name
- NCT05907759
- Testing
- Daratumumab SC
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
HIV Infections, Giant Lymph Node Hyperplasia
Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy
This trial is aimed to study the efficacy of 4 weekly cycles of rituximab in HIV-infected patients with multicentric Castleman disease (giant lymph node hyperplasia) dependent on chemotherapy.
- Trial name
- NCT00127569
- Testing
- Rituximab
- Volunteers
- 25 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Advanced Solid Tumors, Breast Cancer
Dose-escalation Study of Oral CX-4945
This Phase 1 study of oral CX-4945 is designed to test the safety, tolerability and highest safe dose level of this CK2 inhibitor in patients with advanced solid tumor cancers, Castleman's Disease or Multiple Myeloma.
- Conditions
- Advanced Solid Tumors, Breast Cancer, Inflammatory Breast Cancer, Castleman's Disease
- Trial name
- NCT00891280
- Testing
- CX-4945 oral formulation
- Where
- 4 sites in United States
- Volunteers
- 55 people
- Sponsor
- Cylene Pharmaceuticals
KSHV Inflammatory Cytokine Syndrome (KICS), Kaposi Sarcoma Herpesvirus -Associated Multicentric Castleman Disease
Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)
Background: Kaposi sarcoma herpesvirus (KSHV)-associated inflammatory cytokine syndrome (KICS) and KSHV-multicentric Castleman disease (MCD) occur in people living with HIV.
- Trial name
- NCT06052618
- Testing
- Pacritinib
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Multicentric Castleman Disease
Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in Malawi
The purpose of this study is to determine the safety and efficacy of first-line, risk-stratified Rituximab-based Multicentric Castleman Disease (MCD) treatment in Malawi in a single-arm, phase II clinical trial.
- Trial name
- NCT04585893
- Testing
- Rituximab, Etoposide
- Where
- Malawi
- Volunteers
- 15 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Giant Lymph Node Hyperplasia
Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease
The purpose of the study is to learn whether people who are experiencing an MCD (multicentric Castleman's Disease) flare will improve after taking valganciclovir.
- Trial name
- NCT00361933
- Testing
- Valganciclovir
- Sponsor
- University of Washington
Advanced Malignant Neoplasm, Castleman Disease
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
This phase I trial studies the side effects and best dose of bevacizumab and temsirolimus alone or in combination with valproic acid or cetuximab in treating patients with a malignancy that has spread to other places in the body…
- Conditions
- Advanced Malignant Neoplasm, Castleman Disease, Digestive System Carcinoma, Erdheim-Chester Disease
- Trial name
- NCT01552434
- Testing
- Bevacizumab, Cetuximab, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 154 people
- Sponsor
- M.D. Anderson Cancer Center
HHV8, HHV8 Infection
HHV8 and Solid Organ Transplantation
Solid organ transplant candidates will undergo serological screening for HHV8 at time of listing and transplantation. In the event of a recipient/donor mismatch R-/D+ or in the presence of a seropositive recipient (R+), blood…
- Conditions
- HHV8, HHV8 Infection, HHV8-Related Malignant Neoplasm, Kaposi Sarcoma
- Trial name
- NCT05081141
- Testing
- Diagnostic test for HHV8 exposure
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Brain and Central Nervous System Tumors, Lymphoma
Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma
RATIONALE: Imetelstat sodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I clinical trial is studying the side effects and best dose of imetelstat sodium in…
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Lymphoproliferative Disorder, Small Intestine Cancer
- Trial name
- NCT01273090
- Testing
- imetelstat sodium, laboratory biomarker analysis, pharmacological study
- Where
- 23 sites in United States, Canada
- Volunteers
- 34 people
- Sponsor
- Children's Oncology Group
Cancer
BCX-1777 in Treating Patients With Refractory Cancer
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
- Trial name
- NCT00073944
- Testing
- forodesine hydrochloride
- Where
- United States
- Sponsor
- BioCryst Pharmaceuticals
HIV, Kaposi Sarcoma Herpesvirus -Associated Multicentric Castleman Disease
New Approaches for the Diagnosis of Lymphoma and Multicentric Castleman Disease
Persons living with HIV (PLWH) in sub-Saharan Africa (SSA), lymphadenopathy often portends one of a number of life-threatening diseases including tuberculosis, lymphoma, and multicentric Castleman disease (MCD).
- Conditions
- HIV, Kaposi Sarcoma Herpesvirus -Associated Multicentric Castleman Disease, Hodgkin Lymphoma, Non-Hodgkin Lymphoma
- Trial name
- NCT07793006
- Testing
- Lymph Node or Core Needle Biopsy, Fine Needle Aspiration, Tiny Isothermal Nucleic acid Amplification System (TINY)
- Where
- Malawi
- Volunteers
- 500 people
- Sponsor
- Indiana University
Epithelioid Hemangioma of Bone, Epithelioid Hemangioma
Epithelioid Hemangioma of Bone And Soft Tissue
The controversy surrounding epithelioid hemangioma diagnosis stems from its somewhat aggressive clinical characteristics, including multifocal presentation and occasional lymph node involvement.
- Trial name
- EE-META (NCT03169595)
- Testing
- Surgery
- Volunteers
- 70 people
- Sponsor
- Istituto Ortopedico Rizzoli
Multicentric Castleman's Disease
A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease
The purpose of this study is to demonstrate that CNTO 328 when administered in combination with best supportive care (BSC) is superior to BSC in terms of durable tumor and symptomatic response (complete response or partial…
- Trial name
- NCT01024036
- Testing
- Siltuximab, Best Supportive Care (BSC)
- Where
- 56 sites in United States, Australia and 21 more
- Volunteers
- 79 people
- Sponsor
- Janssen Research & Development, LLC
Castleman Disease, Multicentric Castleman Disease
Tocilizumab for KSHV-Associated Multicentric Castleman Disease
Background: Kaposi's sarcoma-associated herpes virus (KSHV)-associated multicentric Castleman disease (KSHV-MCD) is caused by a herpes virus known as KSHV.
- Conditions
- Castleman Disease, Multicentric Castleman Disease, Giant Lymph Node Hyperplasia
- Trial name
- NCT01441063
- Testing
- Zidovudine, Tocilizumab, Valganciclovir (VGC)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Castleman Disease, Unicentric Castleman Disease
Unicentric Form of Castleman Disease - Surgery Therapy Benefit
Observation study on patients with unicentric form of Castleman disease, evaluation of surgical treatment benefit. Observation of surgical treatment strategy.
- Conditions
- Castleman Disease, Unicentric Castleman Disease, Surgery
- Trial name
- NCT05440305
- Testing
- surgery type/exstirpation/debulking
- Volunteers
- 20 people
- Sponsor
- Charles University, Czech Republic
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs in chemotherapy, such as ifosfamide, carboplatin, and etoposide, work in different ways to stop the growth of…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00788125
- Testing
- carboplatin, dasatinib, etoposide phosphate
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- City of Hope Medical Center
Multiple Myeloma, Amyloidosis
A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
The primary aim is to establish a prospective cohort of patients with plasma cell disorders (PCDs). All of the hospitalized PCD patients who are willing to sign the informed consent form (ICF) will be included in this study.
- Conditions
- Multiple Myeloma, Amyloidosis, Cryoglobulinemia, Castleman's Disease
- Trial name
- NCT05283993
- Testing
- No intervention
- Where
- China
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Idiopathic Multicentric Castleman's Disease
Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease
Phase 2 study to investigate the safety, tolerability, and efficacy of administering increased siltuximab doses to patients with iMCD
- Trial name
- SISREMCAD (NCT04838860)
- Testing
- Siltuximab
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- RECORDATI GROUP
Aids-related Malignancies, Lymphoma
Detecting Anal and Genital Human Papillomavirus Infection and Squamous Intraepithelial Lesions in HIV-Positive Patients Enrolled in AIDS Cancer Clinical Trials
RATIONALE: Diagnostic procedures, such as anal swab collection, digital rectal examination, and anal endoscopy and biopsy, may help find and diagnose anal and genital human papillomavirus infection and squamous intraepithelial…
- Conditions
- Aids-related Malignancies, Lymphoma, Precancerous Condition, Sarcoma
- Trial name
- NCT00695422
- Testing
- polymerase chain reaction, cytology specimen collection procedure, histological technique
- Where
- 10 sites in United States
- Volunteers
- 47 people
- Sponsor
- AIDS Malignancy Consortium